###begin article-title 0
Polymorphisms of selected Xenobiotic Genes contribute to the development of Papillary Thyroid Cancer susceptibility in Middle Eastern population
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
The xenobiotic enzyme system that enables us to detoxify carcinogens exhibits identifiable genetic polymorphisms that are highly race specific. We hypothesized that polymorphisms of these genes may be associated with risk of thyroid cancer. To evaluate the role of genetic polymorphisms of xenobiotic genes in thyroid cancer, we conducted a hospital-based case-control study in Saudi population.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 264 321 264 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 T3801C, C4887A, GSTP1 A1578G, C2293T, GSTM1, GSTT1</italic>
###xml 323 346 323 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 G590A, NQO*1 C609T</italic>
223 incident papillary thyroid cancer cases and 513 controls recruited from Saudi Arabian population were analyzed for the association between polymorphisms in genes encoding folic acid metabolizing enzymes MTHFR and six xenobiotics-metabolizing enzymes including CYP1A1 T3801C, C4887A, GSTP1 A1578G, C2293T, GSTM1, GSTT1, NAT2 G590A, NQO*1 C609T, using PCR-RELP.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 22 36 22 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 C4887A </italic>
###xml 361 367 361 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 470 476 470 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
Among selected genes, CYP1A1 C4887A genotypes CA, AA and variant allele A demonstrated significant differences and greater risk of developing thyroid cancer comparing to wild type genotype CC (CA vs. CC; p < 0.0001, OR = 1.91, 95% CI = 1.36-2.70, AA vs. CC; p < 0.001, OR = 3.48, 95% CI = 1.74-6.96 and CA+AA vs. CC; p < 0.0001, OR = 2.07, 95% CI = 1.49-2.88). GSTT1 null showed 3.48 times higher risk of developing thyroid cancer (p < 0.0001, 95% CI = 2.48-4.88) while GSTM1 null showed protective effect (p < 0.05, OR = 0.72, 95% CI = 0.52-0.99). Remaining loci demonstrated no significance with risk.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 47 75 47 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GST, GSTM1 and CYP1A1 C4887A</italic>
###xml 77 78 77 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
Of the 9 polymorphisms screened, we identified GST, GSTM1 and CYP1A1 C4887A, may be of importance to disease process and may be associated with papillary thyroid cancer risk in Saudi Arabian population.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 152 153 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 246 247 246 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 329 330 329 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 515 516 515 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 640 641 640 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 923 924 923 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 925 926 925 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1068 1069 1068 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 794 800 <span type="species:ncbi:9606">humans</span>
Thyroid cancer is the most common endocrine malignancy, accounting for 3% of all cancers and is the eighth most common malignancy in the United States [1]. In contrast, in Kuwait, thyroid cancer ranks second, comprising 8% of all female cancers [2] and similar findings have been reported for other countries in the Gulf region [3]. Thyroid cancer is the fourth most common cancer and overall accounting for 6.1% in Saudi Arabia representing 3.8% male and 10.8% female malignant neoplasms, second to breast cancer [4]. Papillary thyroid carcinoma is the predominant type, accounting for almost all (approximately 90%) thyroid malignancies [5]. Although the exact etiology of thyroid cancer remains unknown, exposure to ionizing radiation is the only verified cause of thyroid carcinogenesis in humans, especially when exposure occurs at young age, although dietary iodine deficiency has also been linked to this pathology [6-8]. However, individuals without previous exposure to ionizing radiation can also develop thyroid cancers, usually defined as sporadic tumors [9], suggesting that other risk factors could also be involved in the etiology of sporadic tumors.
###end p 11
###begin p 12
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 268 294 268 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(Phase I Cytochromes P450)</italic>
###xml 301 337 301 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(Phase II Glutathione-S-Transferase)</italic>
###xml 345 374 345 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(quinone oxidoreductase NQO1)</italic>
###xml 381 382 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 491 496 491 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
It has also been suggested that individuals possessing a modified ability to metabolize carcinogens are at increased risk of cancer [10-12]. For this reason, five (5) families of genes encoding for enzymes controlling oxidative stress have attracted our interest CYPs (Phase I Cytochromes P450), GSTs (Phase II Glutathione-S-Transferase), NADPH (quinone oxidoreductase NQO1), NAT (N-acetyltransferases), and gene encoding folic acid metabolizing enzyme, Methylenetetrahydrofolate reductase (MTHFR).
###end p 12
###begin p 13
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 194 200 194 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
MTHFR balances the pool of folate coenzymes in one carbon metabolism of DNA synthesis and methylation, both are implicated in carcinogenesis of many types of cancer. Previous reports concerning MTHFR gene polymorphisms suggests that individuals carrying the less active form of folate metabolizing enzyme will be at greater risk of cancer [10-12].
###end p 13
###begin p 14
###xml 4 5 4 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 249 254 249 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 258 263 258 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 422 427 422 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 431 436 431 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 243 248 <span type="species:ncbi:9606">human</span>
The N-acetyltransferases (NAT) are involved in the metabolism of drugs and environmental toxins. They catalyze the acetyltransfer from acetylcoenzyme A to an aromatic amine, heterocyclic amine or hydrazine compound. Sequence variations in the human NAT1 and NAT2 result in the production of NAT proteins with variable enzyme activity or stability, leading to slow or rapid acetylation. Therefore, genetic polymorphisms in NAT1 and NAT2 have been associated with drug-induced toxicities and disease [13-15].
###end p 14
###begin p 15
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 177 182 177 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NQO1 </italic>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
NQO1 is acytosolic enzyme catalyzing a 2 electron reduction of quinone and preventing their participation in redox cycling and thus inoxidative stress [16]. Polymorphism within NQO1 has shown to be associated with increased risk of myeloid leukemia [17], bladder carcinoma [18].
###end p 15
###begin p 16
###xml 34 67 34 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">polycyclin aromatic hydrocarbons </italic>
###xml 186 193 186 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 </italic>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
CYP1A1 catalyzes the oxidation of polycyclin aromatic hydrocarbons (PAHs) to epoxides and is inducible by PAH. Although several case control studies have reported an association between CYP1A1 polymorphism and susceptibility to a number of adult cancers, others reported no evidence of such association [19-22].
###end p 16
###begin p 17
###xml 524 526 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 718 724 718 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 827 829 827 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 830 832 830 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 876 878 876 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1020 1033 1020 1033 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53, RAS RET </italic>
###xml 1117 1119 1117 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
Glutathione S-transferases (GSTs) are a family of enzymes that carry out a wide range of functions in cells. GSTs also play a role in detoxification of a variety of endogenous and exogenous electrophilic compounds, such as the removal of reactive oxygen species and regeneration of S-thiolated proteins that are products of oxidative stress and the detoxification of carcinogenic compounds. In addition to this, GSTs modulate the induction of other enzymes and proteins important for cellular functions, such as DNA repair [23]. This class of enzymes is therefore important for maintaining cellular genomic integrity and as a result may play an important role in cancer susceptibility. Several studies have shown that GSTM1 0/0 is associated with an increased risk of lung, bladder, gastric, colorectal, and laryngeal cancers [24-28], although not of skin cancer development [29]. Thus carcinogenesis could be related to the absence of the functional GSTM1 alleles. In the thyroid, many studies related to genes such as p53, RAS RET and thyrotropin receptor have improved our understanding of thyroid carcinogenesis [30].
###end p 17
###begin p 18
###xml 161 224 161 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 T3801C, C4887A, GSTP1 A1578G, GSTP1 C2293T, GSTM1, GSTT1</italic>
###xml 226 249 226 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 G590A, NQO*1 C609T</italic>
We investigated the association between polymorphisms in genes encoding folic acid metabolizing enzymes MTHFR and six xenobiotics-metabolizing enzymes including CYP1A1 T3801C, C4887A, GSTP1 A1578G, GSTP1 C2293T, GSTM1, GSTT1, NAT2 G590A, NQO*1 C609T, since genetic differences in these genes are highly race specific and have never been screened in the Saudi PTC cases. We hypothesized that polymorphisms of genes responsible for drug metabolism xenobiotic genes may be associated with risk of thyroid cancer.
###end p 18
###begin title 19
Methods
###end title 19
###begin title 20
Study Subjects
###end title 20
###begin p 21
###xml 599 601 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 810 812 810 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1013 1034 1013 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1, GSTT1, CYP1A1 </italic>
###xml 1053 1059 1053 1059 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 1066 1072 1066 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 1091 1097 1091 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NQO*1 </italic>
###xml 1107 1112 1107 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 1194 1196 1194 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
###xml 172 179 <span type="species:ncbi:9606">patient</span>
Formalin fixed, paraffin embedded samples from 223 newly presenting and previously untreated Arabian patients with papillary thyroid carcinoma (PTC) were investigated. PTC patient samples (n = 223) were readily available from the archives of the Pathology Department at King Faisal Specialist Hospital and Research Centre (KFSHRC). The Institutional Review Board of the King Faisal Specialist Hospital and Research Centre approved the study in accordance with the Declaration of Helsinki. Diagnosis was confirmed by pathologic review using the diagnostic criteria defined in the WHO Classification [31]. Briefly, tissue cylinders with a diameter of 0.6 mm were punched from representative tumor regions of each "donor" tissue block by using a home made semiautomatic robotic precision instrument as described [32]. Genomic DNA was extracted from paraffin embedded PTC tissues using the Puregene DNA isolation kit (Gentra, Minneapolis, MN) following the manufacturer's recommendations. Genotypes frequency data of GSTM1, GSTT1, CYP1A1 T3801C and C4887A, MTHFR C677T, GSTP1 A1578G and C2293T, NQO*1 C609T and NAT2 G590A for control population utilized in this report was from our previous study [33], briefly, whereby peripheral blood was obtained from age matched, 513 individual healthy blood donors of Middle Eastern Arab origin (95% Saudi Arabians and 5% from other Arab countries such as Jordan, Syria, Lebanon, Yemen) visiting the Blood Bank at KFSHRC, Riyadh, Saudi Arabia.
###end p 21
###begin title 22
Genotyping
###end title 22
###begin p 23
###xml 305 307 303 305 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
We first determined that the use of Hotstart Taq polymerase allowed us to apply the same PCR conditions to optimally amplify each of the variant alleles for all genes studied. PCR reactions were performed in 25 mul containing 50 ng of genomic DNA, 12.5 pmol each primer, 200 muM of each dNTPs, 2.5 mM MgCl2 and 0.5 units Hotstart Taq DNA Polymerase. After denaturation for 10 minutes at 95degreesC, each PCR was performed for 35 cycles of 1 minute at 95degreesC, 1 minute at 59degreesC and 1.5 minutes at 72degreesC. The final elongation step was 10 minutes. Negative non-template controls were included in each PCR. The same aliquot of DNA was used to analyze all SNPs. PCR products were directly analyzed on a 2.5% agarose gel.
###end p 23
###begin title 24
MTHFR Polymorphisms
###end title 24
###begin p 25
###xml 0 12 0 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR C677T </italic>
###xml 105 117 105 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR C677T </italic>
###xml 167 173 167 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 244 256 244 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR C677T </italic>
MTHFR C677T was amplified using primers: (5-TGAAGGAGAAGGTGTCTGCGGGA-3 and 5-AGGACGGTGCGGTGAGAGTG-3), the MTHFR C677T genotypes CC (wildtype) produced one 198-bp band, MTHFR TT (homozygote mutation) produced two bands of 175-bp and 23-bp, while MTHFR C677T CT (heterozygote) samples exhibited a digestion pattern of all three bands when digested with Hinf I.
###end p 25
###begin title 26
CYP1A1 Polymorphisms
###end title 26
###begin p 27
###xml 77 91 77 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 T3801C </italic>
###xml 218 232 218 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 T3801C </italic>
###xml 333 347 333 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 C4887A </italic>
###xml 509 523 509 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 C4887A </italic>
###xml 577 591 577 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 C4887A </italic>
###xml 651 665 651 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 C4887A </italic>
Using primers: (5-GGCTGAGCAATCTGACCCTA-3 and 5-TAGGAGTCTTGTCTCATGCCT-3), the CYP1A1 T3801C genotypes TT (wildtype) produced a 341-bp band, CYP1A1 CC (homozygote mutation) produced two bands of 175-bp and 166-bp, while CYP1A1 T3801C TC (heterozygote) samples exhibited a digestion pattern of all three bands when digested with MSP I. CYP1A1 C4887A gene (rs1048943) was determined using primers (5-CTGTCTCCCTCTGGTTACAGGAAGC-3 and 5-TTCCACCCGTTGCAGCAGGATAGCC-3), and Bsa I was used to digest the 204-bp product: CYP1A1 C4887A CC (wildtype) produced two bands, a 138-bp and 66-bp, CYP1A1 C4887A AA (homozygote mutation) produced one band of 204-bp, while CYP1A1 C4887A CA (heterozygote) samples exhibited a digestion pattern of all three bands (204-bp, 138-bp and 66-bp) when digested with Bsa I.
###end p 27
###begin title 28
GSTP1 Polymorphisms
###end title 28
###begin p 29
###xml 83 96 83 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 A1578G </italic>
###xml 154 160 154 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 231 244 231 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 A1578G </italic>
###xml 437 450 437 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 C2293T </italic>
###xml 516 529 516 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 C2293T </italic>
###xml 589 602 589 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 C2293T </italic>
Using primers: (5-GGCTCTATGGGAAGGACCAGCAGG-3 and 5-GCACCTCCATCCAGAAACTGGCG-3), the GSTP1 A1578G (rs947894) genotype AA (wildtype) produced a 256-bp band, GSTP1 GG (homozygote mutation) produced two bands of 204-bp and 52-bp, while GSTP1 A1578G AG (heterozygote) samples exhibited a digestion pattern of all three bands when digested with BsmA I. Similarly, using primers: (5-CAGCAGAGGCAGCGTGTGTGC-3 and 5-CCCACAATGAAGGTCTTGCCTCC-3), the GSTP1 C2293T (rs1799811) CC (wildtype) produced two bands, a 120-bp and 97-bp, GSTP1 C2293T TT (homozygote mutation) produced one band of 217-bp, while GSTP1 C2293T CT (heterozygote) samples exhibited a digestion pattern of all three bands (217-bp, 120-bp and 97-bp) when digested with Aci I.
###end p 29
###begin title 30
NQO*1 Polymorphisms
###end title 30
###begin p 31
###xml 0 12 0 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NQO*1 C609T </italic>
###xml 105 117 105 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NQO*1 C609T </italic>
###xml 186 192 186 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NQO*1 </italic>
###xml 272 284 272 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NQO*1 C609T </italic>
NQO*1 C609T was amplified using primers: (5-AGTGGCATTCTGCATTTCTGTG-3 and 5-GATGGACTTGCCCAAGTGATG-3), the NQO*1 C609T genotypes CC (wildtype) produced two bands, a 188-bp and 85-bp band, NQO*1 TT (homozygote mutation) produced three bands of 151-bp, 85-bp and 37-bp, while NQO*1 C609T CT (heterozygote) samples exhibited a digestion pattern of all four bands when digested with Hinf I.
###end p 31
###begin title 32
NAT2 Polymorphisms
###end title 32
###begin p 33
###xml 0 11 0 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 G590A </italic>
###xml 103 114 103 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 G590A </italic>
###xml 194 199 194 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 271 282 271 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 G590A </italic>
NAT2 G590A was amplified using primers: (5-CCTGGACCAAATCAGGAGAG-3 and 5-ACACAAGGGTTTATTTTGTTCC-3), the NAT2 G590A genotypes GG (wildtype) produced three bands, a 170-bp, 139-bp and 112-bp band, NAT2 AA (homozygote mutation) produced two bands of 309-bp and 112-bp, while NAT2 G590A GA (heterozygote) samples exhibited a digestion pattern of all four bands when digested with Taq I.
###end p 33
###begin title 34
GSTM1 and GSTT1 Polymorphisms
###end title 34
###begin p 35
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 142 148 139 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 252 258 249 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 299 311 296 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-globin </italic>
###xml 400 406 394 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 442 454 436 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-globin </italic>
###xml 460 466 451 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 599 605 590 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 630 642 621 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-globin </italic>
The presence or absence of GSTM1 and GSTT1 was determined by multiplex PCR in which beta-globin gene was co-amplified as an internal control. GSTM1 was amplified using primers 5-GAACTCCCTGAAAAGCTAAAGC-3 and 5-GTTGGGCTCAAATATACGGTGG-3. Wherever present GSTM1 produced a 219-bp band along with 110-bp beta-globin amplified with primers 5-ACACAACTGTGTTCACTAGC-3 and 5-CAACTTCATCCACGTTCACC-3. Similarly, GSTT1 produced 480-bp band along with 110 beta-globin band. GSTT1 was amplified using primers 5-TTCCTTACTGGTCCTCACATCTC-3 and 5-TCACCGGATCATGGCCAGCA-3. Absence of 219-bp band for GSTM1 or 480-bp for GSTT1 with the presence of 110 beta-globin was recorded as deleted.
###end p 35
###begin title 36
Statistical Analysis
###end title 36
###begin p 37
Univariate analysis using Chi-square analyses (two-sided) was first performed to compare the differences in genotype and allele frequencies between case and control subjects. The odds ratio (OR) and 95% confidence interval provide a measure for the strength of association, e.g. indicating the increase in the odds of a given benign or malignant thyroid tumor demonstrating a particular genotype compared with the control population. Statistical significance of the differences in the frequency of genotypes was assessed, applying two-sided Fisher's exact test, and odds ratios (ORs) with 95% CI were calculated on the SPSS statistical package (version 11.0). All tests were conducted at the p < 0.05 level of significance.
###end p 37
###begin title 38
Results
###end title 38
###begin p 39
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 10 11 10 11 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 224 225 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 556 557 556 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
Tables 1, 2 provide detailed information on the frequency of the multiple genotypes analyzed. 223 PTC samples were included in this study. Initially, only 50 out of 223 PTC samples were analyzed for 9 SNPs in 7 genes (Table 1). Furthermore, comparing cases with the control study group the association between polymorphisms and the risk to develop thyroid cancer was initially assessed with 50 PTC samples and the SNP's that showed statistical significance were selected to further confirm the finding with larger number of cases analyzed (n = 223) (Table 2).
###end p 39
###begin p 40
###xml 71 79 <span type="species:ncbi:9606">patients</span>
Distribution of polymorphisms in healthy population and thyroid cancer patients (n = 50).
###end p 40
###begin p 41
* Statistical significance of the differences in the frequency of genotypes was assessed, applying two-sided Fisher's exact test to compare between case and control subjects.
###end p 41
###begin p 42
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">$ </sup>
$ The odds ratio (OR) providing a measure for the strength of association demonstrating a particular genotype compared with the control population calculated using the SPSS statistical package (version 11.0).
###end p 42
###begin p 43
###xml 33 49 33 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 and GSTT1 </italic>
P = Present and D = Deletion for GSTM1 and GSTT1 gene
###end p 43
###begin p 44
Distribution of Xenobiotic genes polymorphisms in healthy population and PTC cases (n = 223).
###end p 44
###begin p 45
* Statistical significance of the differences in the frequency of genotypes was assessed, applying two-sided Fisher's exact test to compare between case and control subjects.
###end p 45
###begin p 46
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">$ </sup>
$ The odds ratio (OR) providing a measure for the strength of association demonstrating a particular genotype compared with the control population calculated using the SPSS statistical package (version 11.0).
###end p 46
###begin p 47
###xml 33 49 33 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 and GSTT1 </italic>
P = Present and D = Deletion for GSTM1 and GSTT1 gene
###end p 47
###begin p 48
###xml 16 23 16 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 </italic>
###xml 357 364 357 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 </italic>
###xml 413 414 413 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Frequencies for CYP1A1 C4887A genotypes CC, CA, AA and CA+AA were 16.7%, 71.4%, 11.9% and 83.3% respectively and frequency of A allele was 48% when initial analysis with 50 cases was performed. Genotype CA showed 8.7-fold, AA showed 13.1-fold and CA+AA demonstrated 9.2-fold higher risk, compared with wild type (p < 0.0001). On the other hand, analysis of CYP1A1 T3801C showed no statistical significance (Table 1).
###end p 48
###begin p 49
###xml 9 15 9 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 208 209 208 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Although GSTP1 C2293T, genotype TT accounted for 5% of PTC cases comparing with 1.5% of controls and showed 3.24 fold higher risk to develop thyroid cancer but did not reached to level of significance (Table 1).
###end p 49
###begin p 50
###xml 50 56 50 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 189 195 189 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 341 342 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Among 50 PTC cases, 67.3% were homogenous for the GSTT1 null genotype compared with 25% of controls. Consequently there was 6.24 fold increase in the risk of thyroid cancer associated with GSTT1 null genotype (OR = 6.24). No significant differences were found in the frequency of other genes when 50 cases were compared with controls (Table 1).
###end p 50
###begin p 51
###xml 98 112 98 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 C4887A </italic>
###xml 116 121 116 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1</italic>
###xml 357 363 357 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 367 377 367 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 G590A</italic>
###xml 931 937 931 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 941 952 941 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 G590A </italic>
###xml 1097 1098 1097 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1103 1104 1103 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
Using our selection criteria, in particular two genes from xenobiotic metabolizing enzyme system (CYP1A1 C4887A and GSTT1) were chosen to elaborate the study with further 173 cases, since they have demonstrated high statistical significance and odds ratio when controls were compared to initially analyzed 50 cases form PTC samples. Additionally two genes, GSTM1 and NAT2 G590A, which have shown no statistical significance, were also selected for further analysis to confirm the reliability of our selection criteria. 173 further PTC cases were analyzed for these four genes and compared with control case group to assess the association between polymorphisms and the risk to develop thyroid cancer. Although the initial selection criteria was not deemed statistically powerful due to less number of samples nevertheless provided with the selection of genes to expand the study with statistically significant data. As can be seen GSTM1 and NAT2 G590A genes, demonstrated no significant association with risk estimate compared to control group even when expanded with 173 more PTC samples (tables 1 and 2).
###end p 51
###begin p 52
###xml 38 52 38 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 C4887A </italic>
Among selected genes, frequencies for CYP1A1 C4887A genotypes CC, CA, AA and CA+AA were 47%, 44%, 9% and 53% respectively and frequency of A allele was 31%. Genotypes CA, AA and variant allele A demonstrated significant differences comparing to wild type genotype CC. Odds ratio showed CA has 1.9 fold, while AA has 3.4 fold and variant allele A showed 2 fold greater risk of developing thyroid cancer comparing to wild type.
###end p 52
###begin p 53
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 89 95 89 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 162 168 162 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 248 254 248 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 258 264 258 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 306 307 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
GSTT1 null showed 3.48 times higher risk of developing thyroid cancer (p < 0.0001) while GSTM1 null showed protective effect (p < 0.05, OR = 0.718). Although the GSTT1 null was risk factor (OR = 3.48) to develop PTC (p < 0.0001) but double null of GSTT1 and GSTM1 showed no statistical significance (Table 2).
###end p 53
###begin p 54
###xml 56 62 56 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 222 228 222 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 232 238 232 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 304 310 304 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 314 320 314 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 494 500 494 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
We also investigated whether the prevalence of combined GSTT1 null and GSTM1 null genotype (double-null genotype) was significantly increased in PTC cases compared with controls (Table 2). Among PTC cases, 23.6% were both GSTT1 and GSTM1 null, compared with 17.2% of controls. When individuals with both GSTT1 and GSTM1 were considered as the reference group, analysis demonstrated comparatively lower increased risk (OR = 1.45) in individuals with the double-null genotype than that seen with GSTT1 null alone, but the results did not reach the level of significance.
###end p 54
###begin title 55
Discussion
###end title 55
###begin p 56
###xml 117 122 117 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1</italic>
###xml 124 130 124 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 134 140 134 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 321 329 <span type="species:ncbi:9606">patients</span>
Multiple enzyme pathways are involved in detoxification of chemotherapeutic agents and/or carcinogens. Variations in GSTT1, GSTM1 and GSTP1 have been previously demonstrated to influence drug efficacy and toxicity and also to modify individual susceptibility to cancers [34-39] however, there are scarce data specific to patients with thyroid cancer [40-46]. Host factors may contribute to an individual's risk of developing secondary cancers. Our findings suggest that polymorphisms of certain xenobiotic metabolizing enzyme genes modify the individual susceptibility to develop thyroid cancer in the Saudi population. Our findings from this hospital-based case-control study are not entirely consistent with previous published studies.
###end p 56
###begin p 57
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 491 495 491 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GST </italic>
###xml 590 592 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
GSTs participate in the metabolism of alkylating agents, anthracyclines and steroids and variations in within these genes can significantly influence treatment outcome [35,36]. The different glutathione S-transferase (GST) enzymes have classically been considered as an important part of the cell defense against numerous harmful chemicals and reactive oxygen species (ROS) produced endogenously and in the environment [48-52]. Their importance is suggested by the finding that mutations in GST genes have been associated with susceptibility to various diseases, in particular with cancer [48].
###end p 57
###begin p 58
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 68 74 68 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 184 188 184 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GST </italic>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 402 406 402 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GST </italic>
###xml 498 504 498 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 646 652 646 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 820 822 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 826 828 826 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 829 831 829 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 859 861 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 896 901 896 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 989 995 989 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 1086 1088 1086 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1156 1162 1156 1162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 1166 1172 1166 1172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 1190 1192 1190 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 1257 1262 1257 1262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1</italic>
###xml 1269 1274 1269 1274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1</italic>
###xml 1284 1297 1284 1297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 A1578G </italic>
###xml 1310 1312 1310 1312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1501 1503 1501 1503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 1566 1571 1566 1571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1</italic>
###xml 1572 1577 1572 1577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1</italic>
###xml 1626 1627 1626 1627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1726 1739 1726 1739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 A1578G </italic>
###xml 1789 1802 1789 1802 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 C2293T </italic>
###xml 1056 1064 <span type="species:ncbi:9606">patients</span>
The only three studies published so far on involvement of GSTT1 and GSTM1 null alleles in thyroid cancer risk were carried out in three different regions with different frequencies of GST deletion genotype in general population (Spain, Brazil and Portugal) [45,52,53]. Contrary to our findings the results obtained in three recently published studies [45,52,53] did not show increased risk between the GST polymorphisms and papillary and follicular thyroid cancer susceptibility. We found that the GSTT1 null genotype was associated with high risk (OR = 3.478, p < 0.0001) of developing PTC. Although our findings, showed association between the GSTM1 null genotype with decreased risk against development of PTC (OR = 0.718, p < 0.05) comparing to control group, is consistent with previous reports with other cancers [19,20,52,53] including thyroid cancer [43]. Contrary to our findings Canbay et al., in a short study with 32 thyroid samples and 44 controls demonstrated association of GSTM1 null genotype with high risk of developing thyroid cancer in patients stratified with age [46]. Other thyroid cancer studies showed that only the combination of GSTM1 and GSTT1 null inheritance [53] or only the presence of three potentially risk alleles, namely GSTM1-null, GSTT1-null and GSTP1 A1578G genotype GG [46], leads to significant increase in adjusted odds ratio for papillary and follicular thyroid cancers. These results were not confirmed by the third study conducted on a Spanish population [52]. Our data showed weak association with double null genotypes GSTT1+GSTM1, and risk of PTC (OR = 1.451, p = 0.074) (Table 2). Although with limited number of cases (n = 50) we did not find any statistical association with GSTP1 A1578G genotypes but nonetheless our findings in PTC for GSTP1 C2293T with genotypes TT showed non-significant association with elevated risk of PTC (OR = 3.242).
###end p 58
###begin p 59
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 325 330 325 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 333 335 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 495 504 495 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1/M1 </italic>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 624 626 624 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 682 691 682 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1/M1 </italic>
###xml 787 793 787 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 394 402 <span type="species:ncbi:9606">patients</span>
###xml 434 442 <span type="species:ncbi:9606">patients</span>
###xml 800 808 <span type="species:ncbi:9606">patients</span>
The GSTT1 and GSTM1 null allele frequency among controls in the Brazilian, Spanish and other European studies [52] demonstrated marked variation compared to ours (17.2% vs. 5, 10.3 and 9.2%). Thus, the differences in our finding with published data could indicate role of these genotypes distinct to Saudi population. Morari et al. [53] consistent with our data showed that papillary carcinoma patients (17%) and follicular carcinoma patients (10%) presented a higher prevalence of the combined GSTT1/M1 null genotype than the normal population individuals (5%; OR 2.6; 95% CI, 1.044-6.355; p < 0.05). Similar to others [52,53] our results demonstrated higher frequency of combined GSTT1/M1 null genotype in PTC than in control group 23.6% vs. 17.2%). In addition, the frequency of null GSTT1 in our patients was two fold higher than in control group (53.6% vs. 25%).
###end p 59
###begin p 60
###xml 78 84 78 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 114 120 114 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 257 263 257 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 267 273 267 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
In the present study, an increased risk of developing PTC associated with the GSTT1 null and protective effect of GSTM1 null allele was suggested, although not reaching the statistical significance but demonstrated trend towards increased risk with double, GSTT1 and GSTM1 null genotype.
###end p 60
###begin p 61
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 </italic>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 622 628 622 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1</italic>
###xml 757 771 757 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 C4887A </italic>
###xml 1013 1020 1013 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 </italic>
###xml 1183 1197 1183 1197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 C4887A </italic>
###xml 1225 1227 1225 1227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 1282 1289 1282 1289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 </italic>
###xml 1366 1371 1366 1371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 1410 1429 1410 1429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 (m1 and m2) </italic>
###xml 1483 1488 1483 1488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1</italic>
###xml 1490 1495 1490 1495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1</italic>
###xml 1497 1502 1497 1502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 1504 1509 1504 1509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTO1</italic>
###xml 1527 1531 1527 1531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 1595 1602 1595 1602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 </italic>
###xml 1685 1687 1685 1687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
CYP1A1 genes are associated with higher enzymatic inducibility. Levels of circulating hormone are affected by genetic variability, and analysis of genetic polymorphisms that influence estrogen production may provide insight into its potential role in carcinogenesis. Estrogen exerts pleotropic effects on lymphocyte activation, proliferation, cell cycle progression and apoptosis [56], factors that may influence thyroid cancer risk. Additionally depending on levels, cortisol can either suppress or stimulate immune function, so modulation of its production could potentially influence thyroid cancer risk. In our study, CYP1A1, phenotype AA demonstrated strong association with increased risk of developing PTC (OR = 3.484, p < 0.001). Additionally other CYP1A1 C4887A genotypes CA (OR = 1.914, p < 0.0001) and variant allele A (OR = 2.071, p < 0.0001) also demonstrated two fold high risk of developing PTC compared to the wild type. Recently we also demonstrated significantly high differential expression of CYP1A1 gene in PTC compared to normal counterparts, support the notion and may suggest a possible role for estrogen and possibly other cholesterol metabolites formed via CYP1A1 C4887A in the pathogenesis of PTC [57]. Scarce data is available on the association between CYP1A1 polymorphism and increased susceptibility to thyroid cancer. Recently Bufalo et al., in an extensive study investigating CYP1A1 (m1 and m2) role in thyroid tumorigenesis and its connection with GSTM1, GSTT1, GSTP1, GSTO1, and codon 72 of p53 genotypes, demonstrated an inverse association between germline CYP1A1 inheritance and smoking with the risk of thyroid nodules and papillary carcinomas [58].
###end p 61
###begin p 62
###xml 115 121 115 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1</italic>
###xml 123 128 123 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1</italic>
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1</italic>
###xml 137 143 137 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 147 152 147 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NQO1 </italic>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 254 261 254 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1 </italic>
###xml 272 278 272 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
The reasons for these divergent results are not clear but are likely racial differences because the frequencies of CYP1A1, GSTT1, GSTM1, GSTP1 and NQO1 in our controls were different from those found in other studies [33]. For instance certain SNPs like CYP1A1 A4889G and GSTP1 A1578G were not in Hardy-Weinberg equilibrium in the control samples which is contradicting comparing to other population based data. In order to question the specificity of the assay and to rule out the possibility of uncompleted digestion due to inactivation of enzymes or inhibitors in digestion mixture, we repeated the assays multiple and over period of time. Consistent results were obtained demonstrating this to be the true feature in our population.
###end p 62
###begin p 63
Consideration must also be given to potential limitation of the present study and that is the nature of the control subjects enrolled which weakens the study to be claimed purely case: control. Although controls were matched with respect to age but there was gender differences, with preponderance of male blood donors (25:1). While this initial documentation of allelic frequencies in the Arabs may be biased because of the nature of subjects enrolled (preponderance of male blood donors), previous reports have indicated only minimal influence of age and gender on the distribution of these polymorphisms in a given population.
###end p 63
###begin p 64
###xml 31 38 <span type="species:ncbi:9606">patient</span>
###xml 461 469 <span type="species:ncbi:9606">patients</span>
Additionally, in our study PTC patient samples from paraffin embedded tissues were readily available from the archives of the Pathology Department at King Faisal Specialist Hospital and Research Centre (KFSHRC). Similarly control group was randomly selected from DNA available from peripheral blood samples at institutional Tissue Biorepository Bank at KFSHRC. It would have been ideal to analyze samples from uniform source (tissue only or peripheral blood of patients and controls) but it was not possible in our case since archival samples were used. Since genetic aberrations, that could be present in the tumor but possibly not in the "normal tissue" could confound analyses but to the best of our knowledge there are no such reports suggesting somatic mutations in studied genes in thyroid cases.
###end p 64
###begin p 65
Obviously, further study with a larger sample size is needed to confirm these findings and to examine the interaction between genotypes. However, this study does provide preliminary case-control data on several polymorphisms in genes of the xenobiotic pathways and risk to develop thyroid cancer.
###end p 65
###begin title 66
Conclusion
###end title 66
###begin p 67
###xml 187 216 187 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GST, GSTM1 and CYP1A1 C4887A </italic>
We hypothesized that polymorphisms of genes responsible for drug metabolism xenobiotic genes may be associated with risk of thyroid cancer. Of the 9 polymorphisms screened, we identified GST, GSTM1 and CYP1A1 C4887A may be of importance to this disease process. Obviously, confirmatory studies with larger sample sizes will be needed for other genes that showed no significance with risk, but these findings represent a step toward the understanding of genetic susceptibility to thyroid cancer. If these findings are confirmed, then genotypes could be incorporated into future genetic profiles of thyroid cancer risk and may serve in future cancer prevention efforts or public health responses to accompanying risk factors.
###end p 67
###begin title 68
Competing interests
###end title 68
###begin p 69
The authors declare that they have no competing interests.
###end p 69
###begin title 70
Authors' contributions
###end title 70
###begin p 71
###xml 236 243 <span type="species:ncbi:9606">patient</span>
AKS participated in the data analysis and drafting of the manuscript; MI and MAR took part in the genotyping, managed and analyzed the data and approved the final version of the manuscript; JA and RB participated in analyzing subset of patient samples by sequencing, validating RFLP and approved the final version of the manuscript; SUS participated in collecting the clinical data analysis and approved the final version of the manuscript; FAD, OAS and AAN contributed substantially in acquisition of samples and interpretation of data and also participated in revising and formulating the content. SU participated in the concept and design of the study and approved the final version of the manuscript; KAK was responsible for the conception, funding, design and coordination of the study.
###end p 71
###begin title 72
Pre-publication history
###end title 72
###begin p 73
The pre-publication history for this paper can be accessed here:
###end p 73
###begin p 74

###end p 74
###begin title 75
Acknowledgements
###end title 75
###begin p 76
The authors' thank to Azadali Moorji and Wael Al Haqawi for technical assistance.
###end p 76
###begin article-title 77
Cancer Statistics
###end article-title 77
###begin article-title 78
Benign thyroid disease and dietary factors in thyroid cancer: a case-control study in Kuwait
###end article-title 78
###begin article-title 79
Thyroid Cancer in Yemen
###end article-title 79
###begin article-title 80
Cancer Incidence Report Saudi Arabia 1999-2000
###end article-title 80
###begin article-title 81
A national cancer database report on 53,856 cases of thyroid carcinoma treated in the U. S., 1985-1995
###end article-title 81
###begin article-title 82
Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies
###end article-title 82
###begin article-title 83
Irradiation and second cancers. The thyroid as a case in point
###end article-title 83
###begin article-title 84
Incidence of thyroid cancer in Scandinavia following fallout from atomic bomb testing: an analysis of birth cohorts
###end article-title 84
###begin article-title 85
###xml 61 66 <span type="species:ncbi:9606">human</span>
Mechanisms of mutagenesis in mammalian cells. Application to human thyroid tumours
###end article-title 85
###begin article-title 86
Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia
###end article-title 86
###begin article-title 87
Associations between polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and susceptibility to malignant lymphoma
###end article-title 87
###begin article-title 88
Methylenetetrahydrofolate reductase gene (MTHFR) polymorphisms and reduced risk of malignant lymphoma
###end article-title 88
###begin article-title 89
Pharmacogenetics of the arylamine N-acetyltransferases
###end article-title 89
###begin article-title 90
###xml 24 29 <span type="species:ncbi:9606">human</span>
Pharmacogenetics of the human arylamine N- acetyltransferases
###end article-title 90
###begin article-title 91
Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms
###end article-title 91
###begin article-title 92
###xml 68 73 <span type="species:ncbi:9606">human</span>
Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene
###end article-title 92
###begin article-title 93
###xml 106 114 <span type="species:ncbi:9606">patients</span>
Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia
###end article-title 93
###begin article-title 94
Predisposition towards urolithiasis associated with the NQO1 null-allele
###end article-title 94
###begin article-title 95
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas
###end article-title 95
###begin article-title 96
Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk
###end article-title 96
###begin article-title 97
Role of CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes in the susceptibility to acute leukemias
###end article-title 97
###begin article-title 98
Polymorphisms of drug-metabolizing enzymes and risk of childhood acute lymphoblastic leukemia
###end article-title 98
###begin article-title 99
The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance
###end article-title 99
###begin article-title 100
Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility
###end article-title 100
###begin article-title 101
The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung
###end article-title 101
###begin article-title 102
Glutathione S-transferase M1 and T1 and cytochrome P4501A1 polymorphisms in relation to the risk for benign and malignant head and neck lesions
###end article-title 102
###begin article-title 103
Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) genetic polymorphism and susceptibility to gastric and colorectal adenocarcinoma
###end article-title 103
###begin article-title 104
Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk
###end article-title 104
###begin article-title 105
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Glutathione S-transferase GSTM1 null genotype is not overrepresented in Australian patients with nevoid basal cell carcinoma syndrome or sporadic melanoma
###end article-title 105
###begin article-title 106
Molecular pathogenesis of thyroid cancer: the significance of oncogenes, tumor suppressor genes, and genomic instability
###end article-title 106
###begin article-title 107
Tumors of endocrine organs
###end article-title 107
###begin article-title 108
Tissue micro arrays for miniaturized high throughput molecular profiling of tumors
###end article-title 108
###begin article-title 109
Variable drug metabolism genes in Arab population
###end article-title 109
###begin article-title 110
Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia
###end article-title 110
###begin article-title 111
Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia
###end article-title 111
###begin article-title 112
Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia
###end article-title 112
###begin article-title 113
###xml 87 95 <span type="species:ncbi:9606">patients</span>
Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate
###end article-title 113
###begin article-title 114
###xml 85 93 <span type="species:ncbi:9606">patients</span>
Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia
###end article-title 114
###begin article-title 115
Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia
###end article-title 115
###begin article-title 116
###xml 79 87 <span type="species:ncbi:9606">patients</span>
Transferase S-glutathione class pi gene (GSTP1) polymorphism in thyroid cancer patients
###end article-title 116
###begin article-title 117
Glutathione S-transferase polymorphisms and risk of differentiated thyroid carcinomas: a case-control analysis
###end article-title 117
###begin article-title 118
###xml 46 51 <span type="species:ncbi:9606">human</span>
Basal and induced micronucleus frequencies in human lymphocytes with different GST and NAT2 genetic backgrounds
###end article-title 118
###begin article-title 119
###xml 53 61 <span type="species:ncbi:9606">patients</span>
GSTT1 and M1 polymorphisms in Hurthle thyroid cancer patients
###end article-title 119
###begin article-title 120
GST profiling may be useful in the screening for thyroid nodule malignancy
###end article-title 120
###begin article-title 121
Combined effects of glutathione S-transferase polymorphisms and thyroid cancer risk
###end article-title 121
###begin article-title 122
###xml 87 95 <span type="species:ncbi:9606">patients</span>
Higher glutathione transferase GSTM1 0/0 genotype frequency in young thyroid carcinoma patients
###end article-title 122
###begin article-title 123
Glutathione-associated enzymes in anticancer drug resistance
###end article-title 123
###begin article-title 124
Glutathione-S- transferase family of enzymes
###end article-title 124
###begin article-title 125
Glutathione S-transferase: genetics and role in toxicology
###end article-title 125
###begin article-title 126
Mammalian class theta GST and differential susceptibility to carcinogens: a review
###end article-title 126
###begin article-title 127
Multiple isoforms of mitochondrial glutathione S-transferases and their differential induction under oxidative stress
###end article-title 127
###begin article-title 128
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Glutathione S-transferase polymorphisms in thyroid cancer patients
###end article-title 128
###begin article-title 129
The null genotype of glutathione S-transferase M1 and T1 locus increases the risk for thyroid cancer
###end article-title 129
###begin article-title 130
Gastric marginal zone lymphoma is associated with polymorphisms in genes involved in inflammatory response and antioxidative capacity
###end article-title 130
###begin article-title 131
Association of NAT and GST polymorphisms with non-Hodgkin's lymphoma: a population-based case-control study
###end article-title 131
###begin article-title 132
Diamond B. Estrogen alters thresholds for B cell apoptosis and activation
###end article-title 132
###begin article-title 133
Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy
###end article-title 133
###begin article-title 134
allelic variants
###end article-title 134

